BB Pureos Bioventures
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Venture Capital
Stage Focus
Seed, Early Stage, Series A, Series B, Growth, Late Stage, Pre-IPO
Geographical Focus
United States, United Kingdom, Germany, France, Italy, Denmark, Switzerland, Spain, Luxembourg, Ireland, Austria, Netherlands, Portugal, Sweden, Belgium, Norway, Finland, Poland, Czech Republic, Slovakia
Industries Focus
- Healthcare
- Life Sciences
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Regenerative Medicine
- Oncology
- Neurology
- Cardiology
- Endocrinology
- Infectious Diseases
- Immunology
- Genomics
- Rare Diseases
Investment Size:
5,000,000 to 50,000,000 USD
Investor Details Founded: 2018
BB Pureos Bioventures is a venture capital firm investing exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund's portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with in-depth investment, operating, and clinical expertise, that strives to impact patients' lives by advancing innovative treatments for devastating diseases.
The fund's investment strategy focuses on early-stage companies developing novel biological drugs and emerging modalities such as nucleic acid, cell, and gene therapies. It invests globally, with a primary focus on Switzerland and Europe. The team consists of experienced venture capitalists, biotech entrepreneurs, and drug developers.
Since its inception, Pureos has built a balanced portfolio of pre-clinical and clinical-stage companies. Its initial investments include Alentis Therapeutics AG, AM-Pharma BV, Eyevensys SAS, Imcheck Therapeutics SAS, Lava Therapeutics BV, NovaGo Therapeutics AG, and Vico Therapeutics BV. Company building is an important part of Pureos. It is a Partner of BaseLaunch, a start-up accelerator in Basel, and together with a team of Entrepreneurs-in-Residence, Pureos is working on translating ground-breaking science into novel companies.
Requirements
- Innovative drug development companies
- Focus on novel biological drugs and emerging modalities
- Early-stage companies
- Global investment scope with emphasis on Switzerland and Europe
Contact
[Official Website Hidden]
[HQ Location Hidden]
[Email Hidden]
Portfolio Companies
- Alentis Therapeutics AG
- AM-Pharma BV
- Eyevensys SAS
- Imcheck Therapeutics SAS
- Lava Therapeutics BV
- NovaGo Therapeutics AG
- Vico Therapeutics BV
Mentioned In
-
$24.95
-
$49.95
-
$19.95
-
$19.95
-
$24.95
-
$99.00
Claim this Investor
Are you an official representative of BB Pureos Bioventures?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim